Revitalizing in 2H 2017 1H 2017 Results remains solid. Maintain BUY In-line 1H 2017 Results. Tissue paper remains a growth driver Insulin slowed down, 6-APA positives reflected. Maintain HOLD. Earnings improved but potential yet to be released: Maintain BUY Concerns about Q2 results put to rest. Optics business development will trigger a further re-rating. NEED MORE CONCRETE ACTION TO UNLOCK VALUE 1H 2017 Results In Line With Expectations. Maintain BUY. Lipusu looking gloomy. Execution in doubt. Downgrade to SELL. Weak 1H17 Results Due to Unfavourable Market Conditions